Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$15.89
+2.2%
$0.00
$11.06
$63.00
$310.65M1.5277,644 shs171,070 shs
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.60
-0.2%
$0.57
$0.16
$0.82
$639.84M0.252.88 million shs1.51 million shs
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
$0.07
$0.01
$0.01
$726K1.632.58 million shs2.48 million shs
Stealth BioTherapeutics Corp stock logo
MITO
Stealth BioTherapeutics
$0.32
$0.32
$0.16
$1.03
$23.54M1.46946,105 shsN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$1.15
$1.06
$0.45
$1.68
$57.22M1.57.44 million shs15.01 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
0.00%-0.06%-97.93%-97.93%-97.93%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00%-15.78%+7.02%+87.33%+224.61%
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Stealth BioTherapeutics Corp stock logo
MITO
Stealth BioTherapeutics
0.00%0.00%0.00%0.00%0.00%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.3099 of 5 stars
3.80.00.03.72.41.70.6
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.5677 of 5 stars
0.03.00.00.02.90.80.0
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Stealth BioTherapeutics Corp stock logo
MITO
Stealth BioTherapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.67
Strong Buy$25.0057.33% Upside
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
0.00
N/AN/AN/A
Stealth BioTherapeutics Corp stock logo
MITO
Stealth BioTherapeutics
0.00
N/AN/AN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MITO, CBIO, ELTP, NEOS, and INFI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/20/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$22.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10K31,064.95N/AN/A$8.24 per share1.93
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M7.61$0.02 per share34.91$0.05 per share11.98
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
$2.59M0.00N/AN/A($0.21) per share0.00
Stealth BioTherapeutics Corp stock logo
MITO
Stealth BioTherapeutics
$21.09M1.12N/AN/A($0.79) per share-0.41
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$64.65M0.89N/AN/A($0.12) per share-9.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$37.88M-$46.000.00N/AN/AN/A-293.92%-206.20%N/A
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$20.11MN/A0.00N/A-25.70%-6.92%-3.94%8/14/2025 (Estimated)
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
-$44.37M-$0.46N/AN/AN/A-1,593.93%N/A-113.02%N/A
Stealth BioTherapeutics Corp stock logo
MITO
Stealth BioTherapeutics
-$52.53M-$0.52N/AN/AN/AN/AN/A-142.81%N/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
-$16.90M-$0.34N/AN/AN/A-38.35%N/A-28.46%N/A

Latest MITO, CBIO, ELTP, NEOS, and INFI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/30/2025Q4 2025
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A$0.01N/A$0.02N/A$32.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/AN/AN/AN/AN/A
Stealth BioTherapeutics Corp stock logo
MITO
Stealth BioTherapeutics
N/AN/AN/AN/AN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
2.29
2.29
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.12
3.27
1.90
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/A
1.65
1.65
Stealth BioTherapeutics Corp stock logo
MITO
Stealth BioTherapeutics
N/A
3.68
3.68
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/A
0.66
0.53
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
2619.55 million18.77 millionNo Data
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.07 billion914.31 millionNot Optionable
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
3090.76 million81.86 millionOptionable
Stealth BioTherapeutics Corp stock logo
MITO
Stealth BioTherapeutics
2973.55 millionN/ANot Optionable
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
21349.76 millionN/AOptionable

Recent News About These Companies

MCET MultiCell Technologies, Inc.
NEOS/USD - NeosCoin US Dollar
Konstas and Harris to face Test grilling in Shield clash
Cara Therapeutics, Inc. (CARA)
Presidio Partners 2007 GP, L.P.'s Net Worth
Avenue Bank ready to tap into overlooked market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$15.89 +0.34 (+2.19%)
As of 07/3/2025 12:59 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.60 0.00 (-0.15%)
As of 07/3/2025 12:59 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Infinity Pharmaceuticals stock logo

Infinity Pharmaceuticals NASDAQ:INFI

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

Stealth BioTherapeutics stock logo

Stealth BioTherapeutics NASDAQ:MITO

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Neos Therapeutics stock logo

Neos Therapeutics NASDAQ:NEOS

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.